MCID: ALC006
MIFTS: 61

Alcoholic Hepatitis

Categories: Gastrointestinal diseases, Liver diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Alcoholic Hepatitis

MalaCards integrated aliases for Alcoholic Hepatitis:

Name: Alcoholic Hepatitis 11 75 14 31 33
Acute Alcoholic Liver Disease 11 71
Acute Alcoholic Hepatitis 11 53
Hepatitis, Alcoholic 16 71
Ah - [alcoholic Hepatitis] 33
Hepatitis Alcoholic 53
Ethanol Hepatitis 33

Classifications:



External Ids:

Disease Ontology 11 DOID:12351
ICD9CM 34 571.1
NCIt 49 C34352
SNOMED-CT 68 9953008
ICD10 31 K70.1
UMLS 71 C0001306 C0019187

Summaries for Alcoholic Hepatitis

MalaCards based summary: Alcoholic Hepatitis, also known as acute alcoholic liver disease, is related to hepatitis and alcohol dependence. An important gene associated with Alcoholic Hepatitis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Lecithin and Choline have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and skin, and related phenotypes are no effect and no effect

Wikipedia: 75 Alcoholic hepatitis is hepatitis (inflammation of the liver) due to excessive intake of alcohol.... more...

Related Diseases for Alcoholic Hepatitis

Diseases related to Alcoholic Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1024)
# Related Disease Score Top Affiliating Genes
1 hepatitis 32.6 SLC17A5 KRT18 GPT GGT1 F2
2 alcohol dependence 31.9 TNF SLC17A5 IL1B GPT GGT1 CYP2E1
3 hepatorenal syndrome 31.4 GPT F2 ALB
4 hepatic encephalopathy 31.3 TNF SLC17A5 IL6 GPT F2 ALB
5 fatty liver disease 31.3 TNF TLR4 KRT18 IL6 IL1B GPT
6 nutritional deficiency disease 31.2 IL6 F2 CRP ALB
7 hepatitis a 31.1 TNF TLR4 IL1B IL10 GPT F2
8 cholestasis 31.1 SLC17A5 GPT GGT1 F2
9 acute kidney failure 31.0 IL6 HGF GPT F2 ALB ADAMTS13
10 portal hypertension 30.9 TNF SLC17A5 GPT GGT1 F2 ALB
11 esophageal varix 30.8 GPT F2 CRP ALB
12 alcoholic liver cirrhosis 30.7 TNF IL6 IL1B HGF GPT GGT1
13 liver disease 30.6 TNF SLC17A5 KRT18 IL6 HGF GPT
14 liver cirrhosis 30.6 TNF SLC17A5 LBP IL6 HGF GPT
15 varicose veins 30.5 TNF IL6 ICAM1 F2 CXCL8 CCL2
16 human cytomegalovirus infection 30.5 TNF IL6 IL10
17 kwashiorkor 30.5 SLC17A5 GPT F2 CRP ALB
18 kidney disease 30.5 TNF IL6 HGF CRP CCL2 ALB
19 alcohol use disorder 30.5 TNF TLR4 SLC17A5 IL6 IL1B GPT
20 hepatitis c 30.5 SLC17A5 KRT18 IL6 IL10 GPT GGT1
21 active peptic ulcer disease 30.4 GPT F2 CRP ALB
22 intrahepatic cholestasis 30.4 SLC17A5 GPT GGT1 ALB
23 pneumocystosis 30.4 TNF IL6 IL10 GPT CRP ALB
24 hepatitis e 30.3 TNF IL10 GPT F2 ALB
25 peliosis hepatis 30.3 GPT F2 ALB
26 eclampsia 30.3 TNF IL6 F2 ALB
27 viral hepatitis 30.3 SLC17A5 KRT18 IL6 ICAM1 GPT GGT1
28 non-alcoholic steatohepatitis 30.2 TNF TLR4 KRT18 IL6 IL1B GPT
29 hepatic coma 30.2 HGF GPT F2 ALB
30 invasive aspergillosis 30.2 TNF TLR4 IL6 IL10 CRP
31 splenic infarction 30.2 GPT F2 CRP ALB
32 protein-energy malnutrition 30.2 TNF IL6 GPT ALB
33 mumps 30.2 TNF IL6 IL1B IL10 CXCL8
34 non-alcoholic fatty liver disease 30.2 TNF TLR4 KRT18 IL6 IL1B IL10
35 gilbert syndrome 30.1 GPT F2 CRP ALB
36 infective endocarditis 30.1 IL6 F2 CXCL8 CRP ALB
37 alpha-1-antitrypsin deficiency 30.1 TNF GPT F2 CXCL8 ALB
38 paralytic ileus 30.1 IL6 GPT F2 CRP ALB
39 periodic fever, familial, autosomal dominant 30.1 TNF IL6 IL1B CRP
40 adult-onset still's disease 30.1 TNF IL6 IL1B CRP
41 legionnaire disease 30.1 TNF IL6 IL1B CRP
42 tuberculous peritonitis 30.1 CRP ALB
43 short bowel syndrome 30.1 IL6 IL1B HGF
44 adult respiratory distress syndrome 30.1 TNF LBP IL6 IL1B IL10 CXCL8
45 pancytopenia 30.1 IL6 GPT F2 CRP ALB
46 miliary tuberculosis 30.1 TNF IL10 GPT CRP ALB
47 juvenile rheumatoid arthritis 30.1 TNF IL6 IL1B CRP
48 post-traumatic stress disorder 30.0 IL6 IL1B CRP
49 hepatoblastoma 30.0 TNF KRT18 IL6 HGF CYP2E1
50 drug-induced hepatitis 30.0 TNF GPT F2 CYP2E1 CRP ALB

Comorbidity relations with Alcoholic Hepatitis via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Alcohol Use Disorder
Alcoholic Gastritis Alcoholic Liver Cirrhosis
Alcoholic Neuropathy Deficiency Anemia
Fatty Liver Disease Hepatic Encephalopathy
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Alcoholic Hepatitis:



Diseases related to Alcoholic Hepatitis

Symptoms & Phenotypes for Alcoholic Hepatitis

GenomeRNAi Phenotypes related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ADAMTS13 ALB ALDH2 CCL2 CRP CXCL8
2 no effect GR00402-S-2 10.17 ADAMTS13 ALB ALDH2 CCL2 CRP CYP2E1

MGI Mouse Phenotypes related to Alcoholic Hepatitis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 ADAMTS13 ALB ALDH2 CCL2 CRP CYP2E1
2 growth/size/body region MP:0005378 10.35 ALDH2 CCL2 CYP2E1 F2 GGT1 HGF
3 neoplasm MP:0002006 10.28 ALB ALDH2 CCL2 CYP2E1 ICAM1 IL10
4 liver/biliary system MP:0005370 10.25 ALB ALDH2 CCL2 CYP2E1 HGF IL10
5 cellular MP:0005384 10.25 ALB ALDH2 CCL2 F2 GGT1 HGF
6 cardiovascular system MP:0005385 10.25 ALB ALDH2 CCL2 CRP CYP2E1 F2
7 immune system MP:0005387 10.24 ADAMTS13 ALB ALDH2 CCL2 CRP F2
8 muscle MP:0005369 10.18 ALB ALDH2 CCL2 F2 ICAM1 IL10
9 skeleton MP:0005390 10.1 ALDH2 CCL2 CYP2E1 F2 GGT1 GPT
10 digestive/alimentary MP:0005381 10.06 ALB CCL2 F2 ICAM1 IL10 IL6
11 pigmentation MP:0001186 10.02 ADAMTS13 ALDH2 CCL2 GGT1 HGF TLR4
12 hematopoietic system MP:0005397 9.97 ADAMTS13 ALDH2 CCL2 F2 GGT1 HGF
13 vision/eye MP:0005391 9.96 ADAMTS13 ALDH2 CCL2 GGT1 ICAM1 IL10
14 mortality/aging MP:0010768 9.86 ADAMTS13 ALB ALDH2 CCL2 CYP2E1 F2
15 integument MP:0010771 9.32 ALDH2 CCL2 F2 GGT1 ICAM1 IL10

Drugs & Therapeutics for Alcoholic Hepatitis

Drugs for Alcoholic Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lecithin Approved, Experimental, Investigational, Nutraceutical Phase 4 8002-43-5, 18656-38-7, 1446756-47-3 26197 9547096 6323481
2
Choline Approved, Nutraceutical Phase 4 62-49-7 305
3
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
4
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
5
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
6
Metadoxine Experimental Phase 4 74536-44-0
7 Lipid Regulating Agents Phase 4
8 Antimetabolites Phase 4
9 Polyene phosphatidylcholine Phase 4
10 Hypolipidemic Agents Phase 4
11 Nootropic Agents Phase 4
12 Acidophilus Phase 4
13 Antioxidants Phase 4
14 Micronutrients Phase 4
15 Folate Phase 4
16 Vitamins Phase 4
17 Trace Elements Phase 4
18 Vitamin B9 Phase 4
19 Vitamin B6 Phase 4
20 Vitamin B Complex Phase 4
21 Vitamin B 6 Phase 4
22
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
23
Ginseng Investigational, Nutraceutical Phase 4 50647-08-0
24
Rifaximin Approved, Investigational Phase 3 80621-81-4 46783403 6436173
25
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
26
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
27
Zinc cation Approved, Experimental, Investigational Phase 2, Phase 3 7440-66-6, 23713-49-7 32051
28
Clavulanic acid Approved, Vet_approved Phase 3 58001-44-8 5280980
29
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
30
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
31
Ethanol Approved Phase 3 64-17-5 702
32
Lenograstim Approved, Investigational Phase 3 135968-09-1
33
Cysteine Approved, Nutraceutical Phase 3 52-90-4 594 5862
34 Radiation-Protective Agents Phase 2, Phase 3
35 Platelet Aggregation Inhibitors Phase 2, Phase 3
36 Phosphodiesterase Inhibitors Phase 2, Phase 3
37 Vasodilator Agents Phase 2, Phase 3
38 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
39 Antirheumatic Agents Phase 2, Phase 3
40 Dermatologic Agents Phase 2, Phase 3
41 beta-Lactamase Inhibitors Phase 3
42 Amoxicillin-Potassium Clavulanate Combination Phase 3
43 Antibiotics, Antitubercular Phase 3
44 Anti-Bacterial Agents Phase 3
45 diuretics Phase 3
46 Gastrointestinal Agents Phase 3
47 Liver Extracts Phase 3
48 Immunologic Factors Phase 3
49 Adjuvants, Immunologic Phase 3
50 Antiemetics Phase 3

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline
2 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
3 Granulocyte Colony Stimulating Factor in Alcoholic Hepatitis Unknown status NCT03703674 Phase 4 GCSF
4 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
5 Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis Completed NCT02161653 Phase 4 Prednisone plus Metadoxine;Pentoxifylline plus Metadoxine
6 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
7 Phase 4 Study of High Dose Vitamin C in Chronic Hepatitis Patients Completed NCT01413360 Phase 4 High dose vitamin C
8 Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis Unknown status NCT02485106 Phase 3 Rifaximin;Corticosteroid or pentoxifylline
9 Principal Investigator Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
10 Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study. Completed NCT00863785 Phase 3 Corticoids plus N Acetyl Cysteine
11 Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3 Pentoxifylline;placebo
12 N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial Completed NCT00962442 Phase 3 N-Acetylcysteine;placebo
13 Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis Completed NCT01809132 Phase 2, Phase 3 Anakinra;Pentoxifylline;Zinc Sulfate;Methylprednisolone
14 Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis Completed NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
15 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Completed NCT01471028 Phase 3
16 Fecal Microbial Transplantation for Corticosteroids Non-responders and Non-eligible Patients With Severe Alcoholic Hepatitis Recruiting NCT04758806 Phase 3
17 The Mechanism of Action of N-acetylcysteine for Reducing the Risk of Infection in Alcoholic Hepatitis Recruiting NCT03069300 Phase 3 N-acetyl cysteine (NAC)
18 Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial Recruiting NCT02473341 Phase 3 Bovine Colostrum;Placebo
19 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
20 Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study Terminated NCT02442180 Phase 3 G-CSF (Filgrastim injection);steroid;placebo
21 A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Terminated NCT02612428 Phase 3
22 Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study Unknown status NCT02116556 Phase 2 Prednisone;Rifaximin
23 A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis Completed NCT02019056 Phase 2 Placebo /bid P.O;MG-1;MG-2 : MG1000mg, Placebo /bid P.O;metadoxine
24 An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis Completed NCT03432260 Phase 2 DUR-928
25 A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Subjects With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
26 A Multicenter, Randomized, Double Blinded, Placebo-controlled Clinical Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis by the AlcHepNet Consortium Completed NCT04072822 Phase 2 Anakinra and Zinc;Prednisone;Placebos
27 A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis Completed NCT02776059 Phase 2 Standard of care + pegfiltrastim;Standard of care
28 Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis Completed NCT03829683 Phase 2 Vitamin C;Dextrose 5% in water
29 A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis Completed NCT01968382 Phase 2 IMM 124-E (Hyperimmune Bovine Colostrum);Placebo (High protein milk powder)
30 Efficacy of Combination Therapy of Glucocorticoids, and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis: A Pilot Study. Completed NCT02265328 Phase 2
31 An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis Completed NCT02655510 Phase 1, Phase 2 F-652
32 A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Mycophenolate Mofetil and Rilonacept (Anti-interleukin-1) in Patients With Alcoholic Hepatitis Completed NCT01903798 Phase 2 Mycophenolate mofetil;Prednisolone;Rilonacept
33 Effect of Oral S-Adenosylmethionine Administration on Abnormalities of Hepatic Methionine Metabolism and Disease Progression in Alcoholic Liver Disease. A Randomized, Double Blind, Placebo-controlled Trial Completed NCT00851981 Phase 2
34 U01 Pilot Trial of DUR-928 in Patients With Moderate and Severe Alcoholic Hepatitis Recruiting NCT03917407 Phase 2 DUR-928 (Moderate AH);DUR-928 (Severe AH)
35 A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Alcoholic Hepatitis Recruiting NCT04563026 Phase 2 DUR-928 30 mg;DUR-928 90 mg;Placebo+ Standard of Care (SOC)
36 Digoxin In Treatment of Alcohol Associated Hepatitis (DIGIT-AlcHep) Recruiting NCT05014087 Phase 2 Intravenous digoxin
37 IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH) Active, not recruiting NCT03775109 Phase 2 Canakinumab 150mg/ml solution for injection;Placebo
38 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-242 in Subjects With Acute Alcoholic Hepatitis Causing Decompensation of Alcohol-related Cirrhosis and Acute-on-Chronic Liver Failure Not yet recruiting NCT04620148 Phase 2 TAK-242;Placebo
39 A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis. Terminated NCT03452540 Phase 2 1000mg DS102 (BID)
40 A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Terminated NCT02039219 Phase 2 Placebo;10 mg Obeticholic Acid (OCA)
41 A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy Terminated NCT01912404 Phase 2 IDN-6556;Placebo
42 A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure Terminated NCT01937130 Phase 2 IDN-6556
43 Arginine Treatment for Alcoholic Hepatitis Withdrawn NCT00200746 Phase 2 Arginine
44 Fecal Microbiome Changes Characterization and Safety Evaluation After Oral Administration of Lyophilized Capsules Containing Microbiota Suspension in Severe Alcoholic Hepatitis Patients: Double Blinded, Randomized, Placebo-Controlled Study. Recruiting NCT05006430 Phase 1
45 A Pilot Study of Pentoxifylline-Therapy for Acute Alcoholic Hepatitis Terminated NCT00205049 Phase 1 pentoxifylline
46 A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis A Randomized Controlled Trial. Unknown status NCT03091010 Steroids
47 Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients -A Randomized Controlled Trial. Unknown status NCT04066179 Gcsf;Prednisolone
48 Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis- Assessment of Impact on Prognosis and Short-term Outcome Unknown status NCT03827772
49 Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN). Unknown status NCT04142723
50 G-CSF in Acute Liver Failure and Alcoholic Hepatitis - A Pilot Study Unknown status NCT01341951 Granulocyte colony stimulating factor

Search NIH Clinical Center for Alcoholic Hepatitis

Genetic Tests for Alcoholic Hepatitis

Anatomical Context for Alcoholic Hepatitis

Organs/tissues related to Alcoholic Hepatitis:

MalaCards : Liver, Brain, Skin, Neutrophil, Bone Marrow, Monocytes, T Cells

Publications for Alcoholic Hepatitis

Articles related to Alcoholic Hepatitis:

(show top 50) (show all 3107)
# Title Authors PMID Year
1
Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia. 53 62
19094193 2010
2
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 53 62
19769633 2009
3
Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. 53 62
19834427 2009
4
[Hepato-biliary and pancreatic disease and osteodystrophy]. 53 62
19721198 2009
5
[Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors]. 53 62
19663083 2009
6
Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. 53 62
18618253 2009
7
Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. 53 62
19175915 2009
8
Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. 53 62
19033535 2009
9
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. 53 62
18848937 2008
10
Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. 53 62
19038698 2008
11
Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. 53 62
18687753 2008
12
Serum TNF-alpha levels in relation to alcohol consumption and common TNF gene polymorphisms. 53 62
18579335 2008
13
Potential role of ADAMTS13 in the progression of alcoholic hepatitis. 53 62
19630717 2008
14
The -308 TNFalpha gene polymorphism in severe acute alcoholic hepatitis: identification of a new susceptibility marker. 53 62
18336639 2008
15
High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. 53 62
17498256 2007
16
Serum concentrations of interleukin-8 in relation to different levels of alcohol consumption. 53 62
17576072 2007
17
[Utility of analytical parameters in the diagnosis of liver disease]. 53 62
17373869 2007
18
Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. 53 62
17331172 2007
19
Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. 53 62
17331163 2007
20
New treatments of hepatorenal syndrome. 53 62
16850375 2006
21
Combined polymorphisms of tumour necrosis factor alpha and interleukin-10 genes in patients with alcoholic hepatitis. 53 62
16702858 2006
22
[Serum cytokine concentration as prognostic factor in patients with alcoholic liver disease]. 53 62
17036498 2006
23
Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. 53 62
16762691 2006
24
Severe alcoholic hepatitis with extremely high neutrophil count successfully treated by granulocytapheresis. 53 62
16508230 2006
25
Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. 53 62
16385229 2005
26
[Genetic susceptibility to the development of acute alcoholic hepatitis: role of genetic mutations in dehydrogenase alcohol, aldehyde dehydrogenase and cytochrome P450 2E1]. 53 62
16324524 2005
27
Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. 53 62
16344606 2005
28
Apoptosis in liver diseases--detection and therapeutic applications. 53 62
16258409 2005
29
Modifications in P62 occur due to proteasome inhibition in alcoholic liver disease. 53 62
15964033 2005
30
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. 53 62
16009691 2005
31
Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. 53 62
15878216 2005
32
Expression of apolipoprotein AI mRNA in peripheral white blood cells of patients with alcoholic liver disease. 53 62
15949702 2005
33
Balance between pro and anti-inflammatory cytokines in patients with acute alcoholic hepatitis. 53 62
15864177 2005
34
Effects of acetaldehyde and TNF alpha on the inhibitory kappa B-alpha protein and nuclear factor kappa B activation in hepatic stellate cells. 53 62
15550448 2005
35
Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. 53 62
15601573 2004
36
Relation of tumor necrosis factor (TNF) gene polymorphisms with serum concentrations and in vitro production of TNF-alpha and interleukin-8 in heavy drinkers. 53 62
15902922 2004
37
Serum levels of tissue polypeptide specific antigen are correlated with hepatocyte cytokeratin expression in alcoholic liver disease. 53 62
15365314 2004
38
Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. 53 62
15331349 2004
39
Diagnosis and therapy of alcoholic liver disease. 53 62
15349802 2004
40
Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. 53 62
15288471 2004
41
Effect of prostaglandin E receptor subtype EP4 selective agonist on the secretion of tumor necrosis factor-alpha by macrophages in acute ethanol-loaded rats. 53 62
15318098 2004
42
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. 53 62
15122768 2004
43
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. 53 62
15046213 2004
44
New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. 53 62
14720455 2004
45
The effect of alcohol consumption on endothelial adhesion molecule expression. 53 62
14690873 2003
46
Hepatorenal syndrome. 53 62
14654322 2003
47
Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. 53 62
12865279 2003
48
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. 53 62
12663232 2003
49
Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? 53 62
12663246 2003
50
Tumor necrosis factor alpha (TNF-alpha)-induced RANTES chemokine expression via activation of NF-kappaB and p38 MAP kinase: roles of TNF-alpha in alcoholic liver diseases. 53 62
12663241 2003

Variations for Alcoholic Hepatitis

Expression for Alcoholic Hepatitis

LifeMap Discovery
Genes differentially expressed in tissues of Alcoholic Hepatitis patients vs. healthy controls: 35 (show top 50) (show all 111)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 AKR1B10 aldo-keto reductase family 1 member B10 Liver + 8.79 0.000
2 KRT23 keratin 23 Liver + 7.04 0.000
3 FOS Fos proto-oncogene, AP-1 transcription factor subunit Liver - 6.75 0.000
4 CCL20 C-C motif chemokine ligand 20 Liver + 6.56 0.000
5 KCNN2 potassium calcium-activated channel subfamily N member 2 Liver - 6.11 0.000
6 SPINK1 serine peptidase inhibitor Kazal type 1 Liver + 6.07 0.000
7 SPP1 secreted phosphoprotein 1 Liver + 6.04 0.000
8 LCN2 lipocalin 2 Liver + 5.74 0.000
9 CXCL6 C-X-C motif chemokine ligand 6 Liver + 5.55 0.000
10 COL1A2 collagen type I alpha 2 chain Liver + 5.33 0.000
11 FOSB FosB proto-oncogene, AP-1 transcription factor subunit Liver - 5.08 0.000
12 LOXL4 lysyl oxidase like 4 Liver + 5.01 0.000
13 PDZK1IP1 PDZK1 interacting protein 1 Liver + 4.95 0.000
14 CYP1A2 cytochrome P450 family 1 subfamily A member 2 Liver - 4.91 0.000
15 GOLM1 golgi membrane protein 1 Liver + 4.87 0.000
16 NR4A2 nuclear receptor subfamily 4 group A member 2 Liver - 4.85 0.000
17 MMP7 matrix metallopeptidase 7 Liver + 4.73 0.000
18 EFEMP1 EGF containing fibulin extracellular matrix protein 1 Liver + 4.63 0.000
19 CD24 CD24 molecule Liver + 4.57 0.000
20 GNMT glycine N-methyltransferase Liver - 4.50 0.000
21 PCOLCE2 procollagen C-endopeptidase enhancer 2 Liver - 4.48 0.000
22 CYP2C19 cytochrome P450 family 2 subfamily C member 19 Liver - 4.45 0.000
23 TACSTD2 tumor associated calcium signal transducer 2 Liver + 4.41 0.000
24 DCDC2 doublecortin domain containing 2 Liver + 4.28 0.000
25 EPCAM epithelial cell adhesion molecule Liver + 4.26 0.000
26 NQO1 NAD(P)H quinone dehydrogenase 1 Liver + 4.10 0.000
27 MT1M metallothionein 1M Liver - 4.07 0.000
28 SOX9 SRY-box transcription factor 9 Liver + 3.99 0.000
29 THBS2 thrombospondin 2 Liver + 3.98 0.000
30 KRT7 keratin 7 Liver + 3.96 0.000
31 BICC1 BicC family RNA binding protein 1 Liver + 3.96 0.000
32 FABP4 fatty acid binding protein 4 Liver + 3.94 0.000
33 IL32 interleukin 32 Liver + 3.94 0.000
34 PPP1R1A protein phosphatase 1 regulatory inhibitor subunit 1A Liver - 3.91 0.000
35 RRM2 ribonucleotide reductase regulatory subunit M2 Liver + 3.90 0.000
36 CXCL8 C-X-C motif chemokine ligand 8 Liver + 3.90 0.000
37 VCAN versican Liver + 3.90 0.000
38 COL1A1 collagen type I alpha 1 chain Liver + 3.89 0.000
39 DUSP1 dual specificity phosphatase 1 Liver - 3.89 0.000
40 LGSN lengsin, lens protein with glutamine synthetase domain Liver - 3.78 0.000
41 COL5A1 collagen type V alpha 1 chain Liver + 3.77 0.000
42 SERPINE1 serpin family E member 1 Liver - 3.77 0.000
43 RGS4 regulator of G protein signaling 4 Liver + 3.76 0.000
44 STMN2 stathmin 2 Liver + 3.72 0.000
45 SOX4 SRY-box transcription factor 4 Liver + 3.71 0.000
46 CLEC4M C-type lectin domain family 4 member M Liver - 3.69 0.000
47 ANXA2 annexin A2 Liver + 3.67 0.000
48 ANXA2P2 annexin A2 pseudogene 2 Liver + 3.66 0.000
49 CNDP1 carnosine dipeptidase 1 Liver - 3.65 0.000
50 GPR88 G protein-coupled receptor 88 Liver - 3.64 0.000
Search GEO for disease gene expression data for Alcoholic Hepatitis.

Pathways for Alcoholic Hepatitis

Pathways related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CCL2 CRP CXCL8 F2 HGF ICAM1
2
Show member pathways
13.67 TNF TLR4 IL6 IL1B IL10 HGF
3
Show member pathways
13.58 TNF IL6 IL1B IL10 ICAM1 HGF
4
Show member pathways
13.45 TNF TLR4 IL6 IL1B IL10 HGF
5
Show member pathways
13.37 TNF LBP IL6 IL1B IL10 ICAM1
6
Show member pathways
13.33 TNF IL6 IL1B IL10 HGF CXCL8
7
Show member pathways
12.9 TNF TLR4 LBP IL6 IL1B CXCL8
8
Show member pathways
12.78 TNF IL1B HGF GGT1 CCL2
9
Show member pathways
12.74 TNF TLR4 IL6 IL1B HGF
10 12.72 CCL2 HGF IL10 IL1B IL6
11
Show member pathways
12.68 TNF IL6 IL1B IL10 HGF CXCL8
12
Show member pathways
12.67 CCL2 F2 IL10 IL1B IL6 TNF
13
Show member pathways
12.58 TNF TLR4 IL6 IL1B CXCL8
14
Show member pathways
12.49 TNF TLR4 LBP IL6 IL1B CXCL8
15
Show member pathways
12.4 TNF TLR4 LBP IL6 IL1B CXCL8
16
Show member pathways
12.31 TNF IL6 CXCL8 CCL2
17 12.26 TNF IL6 IL1B IL10 CXCL8
18 12.15 TNF IL6 IL1B IL10
19
Show member pathways
12.01 IL10 IL1B IL6 TLR4 TNF
20 11.97 IL6 IL10 CXCL8 CCL2
21
Show member pathways
11.96 TLR4 LBP IL6 ICAM1 CXCL8
22 11.95 TNF IL1B IL10 CXCL8
23
Show member pathways
11.86 LBP IL6 CXCL8 CRP CCL2
24 11.86 TNF TLR4 IL6 IL1B ICAM1 CXCL8
25 11.84 TNF IL6 IL1B IL10
26 11.81 TNF IL1B IL10
27 11.81 IL6 IL10 CXCL8 CCL2
28 11.81 TNF TLR4 IL6 IL10 CRP
29 11.79 IL6 ICAM1 CXCL8
30 11.78 TLR4 IL6 IL10
31
Show member pathways
11.73 TNF TLR4 IL6 IL10
32
Show member pathways
11.73 CXCL8 ICAM1 IL1B IL6 TNF
33 11.71 TNF TLR4 IL6 IL1B IL10
34 11.67 TNF IL10 ICAM1 CCL2
35 11.65 TNF IL10 CXCL8 CCL2
36 11.64 CCL2 CXCL8 HGF IL1B IL6 TNF
37 11.63 TNF TLR4 LBP
38 11.62 TNF TLR4 LBP
39 11.62 TNF TLR4 IL1B CCL2
40 11.6 TNF TLR4 IL6 CXCL8 CCL2
41 11.59 TNF IL6 CYP2E1 CCL2
42 11.59 TNF TLR4 IL6 IL10 ICAM1 CXCL8
43 11.54 TNF IL6 IL1B
44 11.54 LBP IL6 CRP
45 11.51 TNF TLR4 LBP IL6 CCL2
46 11.43 TNF TLR4 IL6 IL1B ICAM1 HGF
47 11.42 IL6 CXCL8 CCL2
48 11.4 TNF TLR4 IL6 IL1B IL10
49 11.38 IL1B IL6 TNF
50 11.37 TNF IL6 IL1B IL10 ICAM1 CXCL8

GO Terms for Alcoholic Hepatitis

Cellular components related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 TNF LBP IL6 IL1B IL10 HGF
2 extracellular space GO:0005615 9.78 ADAMTS13 ALB CCL2 CRP CXCL8 F2

Biological processes related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.37 TNF TLR4 IL6 IL1B CXCL8 CRP
2 positive regulation of DNA-binding transcription factor activity GO:0051091 10.24 IL10 IL1B IL6 TNF
3 cellular response to type II interferon GO:0071346 10.22 TNF TLR4 CCL2 ADAMTS13
4 immune response GO:0006955 10.22 TNF TLR4 IL6 IL1B IL10 CXCL8
5 neutrophil chemotaxis GO:0030593 10.2 LBP IL1B CXCL8 CCL2
6 defense response to Gram-positive bacterium GO:0050830 10.19 CRP IL1B IL6 LBP TNF
7 negative regulation of interleukin-6 production GO:0032715 10.16 TNF TLR4 IL10 HGF
8 response to lipopolysaccharide GO:0032496 10.15 TNF TLR4 LBP IL1B IL10
9 cellular response to amyloid-beta GO:1904646 10.14 TNF TLR4 ICAM1
10 positive regulation of nitric oxide biosynthetic process GO:0045429 10.13 TNF TLR4 IL1B
11 positive regulation of interleukin-10 production GO:0032733 10.13 TLR4 IL6 HGF
12 response to bacterium GO:0009617 10.11 TNF TLR4 SLC17A5 CYP2E1 CCL2
13 liver regeneration GO:0097421 10.1 TNF IL6 IL10
14 positive regulation of interleukin-6 production GO:0032755 10.1 IL1B IL6 LBP TLR4 TNF
15 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.09 IL6 TLR4 TNF
16 negative regulation of neurogenesis GO:0050768 10.08 TNF IL6 IL1B
17 positive regulation of macrophage activation GO:0043032 10.06 TLR4 LBP IL10
18 positive regulation of glial cell proliferation GO:0060252 10.05 IL1B IL6 TNF
19 acute-phase response GO:0006953 10.03 LBP IL6 F2 CRP
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.01 IL10 IL1B TNF
21 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.97 TNF IL6 IL10 F2
22 negative regulation of cytokine production involved in immune response GO:0002719 9.96 TNF IL10
23 positive regulation of interleukin-8 production GO:0032757 9.96 TNF TLR4 LBP IL6 IL1B
24 positive regulation of fever generation GO:0031622 9.95 TNF IL1B
25 positive regulation of neuroinflammatory response GO:0150078 9.95 TNF IL6 IL1B
26 sequestering of triglyceride GO:0030730 9.94 TNF IL1B
27 leukocyte migration GO:0050900 9.93 TNF IL1B ICAM1
28 negative regulation of lipid storage GO:0010888 9.93 TNF IL6 CRP
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.92 TNF IL1B
30 chronic inflammatory response to antigenic stimulus GO:0002439 9.89 TNF IL10
31 positive regulation of chemokine production GO:0032722 9.81 IL1B IL6 LBP TLR4 TNF
32 vascular endothelial growth factor production GO:0010573 9.8 TNF IL6 IL1B
33 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 TNF TLR4 LBP IL1B CCL2
34 cellular response to lipopolysaccharide GO:0071222 9.55 TNF TLR4 LBP IL6 IL1B IL10

Molecular functions related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.73 TNF TLR4 LBP IL6 HGF F2
2 lipopolysaccharide binding GO:0001530 9.63 TLR4 LBP F2
3 cytokine activity GO:0005125 9.32 TNF IL6 IL1B IL10 CXCL8 CCL2

Sources for Alcoholic Hepatitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....